deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06171789

PRO1107 in Patients With Advanced Solid Tumors

A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors

Sponsor: Genmab

Conditions Endometrial Cancer GastroEsophageal Cancer Non-small Cell Lung Cancer Ovarian Cancer Triple Negative Breast Cancer Urothelial Carcinoma
Interventions GEN1107
Updated 17 times since 2024 Last updated: Feb 23, 2026 Started: Jan 3, 2024 Primary completion: Aug 18, 2025 Completion: Aug 18, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation

Other terminated trials from Genmab

See all terminations from Genmab

Other Endometrial Cancer trials with similar outcome

Browse all Endometrial Cancer trials

This PHASE1/PHASE2 trial investigates Endometrial Cancer and GastroEsophageal Cancer and is currently terminated or withdrawn. Genmab leads this study, which shows 17 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshotTerminated~Feb 2026 – present · 6 months · monthly snapshotTerminated

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Oct 2025 — Feb 2026 [monthly]

    Terminated PHASE1/PHASE2

    Status: Active Not Recruiting → Terminated

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 12 earlier versions

  1. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  6. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  7. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  8. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  9. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  10. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Feb 2024 — Mar 2024 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. Jan 2024 — Feb 2024 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genmab
Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations